UOC
PTCT icon

UBS O'Connor’s PTC Therapeutics PTCT Stock Holding History

UBS O'Connor’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$44.5K – 623
2024
Q1 		$44.5K Sell
20,000
-30,000
-60% -$840K ﹤0.01% 446
2023
Q4 		$119K Buy
+50,000
New +$1.14M ﹤0.01% 408
2023
Q3 		– Sell
-27,500
Closed -$34.4K – 613
2023
Q2 		$34.4K Buy
+27,500
New +$1.35M ﹤0.01% 515

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's PTCT Position: Q3 2025 in Review

UBS O'Connor sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 14,548 shares — an estimated $711K sold.

UBS O'Connor first reported a position in PTCT in Q3 2015 and held it in 13 quarters. The position peaked at $2.65M in Q1 2023. 294 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • UBS O'Connor reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 14,548 PTC Therapeutics shares in Q3 2025, an estimated $711K.
  • UBS O'Connor first reported a position in PTC Therapeutics in Q3 2015 and held it in 13 quarters.
  • UBS O'Connor's PTC Therapeutics position peaked at $2.65M in Q1 2023.
  • 294 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.